Pharmacokinetics of combined treatment with praziquantel and albendazole in neurocysticercosis

British Journal of Clinical Pharmacology

Volumn 72, Issue 1, 2011, Pages 77-84

  Garcia, Hector H ^a,b   Lescano, Andres G ^b,c   Lanchote, Vera L ^d   Pretell, E Javier ^a,b   Gonzales, Isidro ^a   Bustos, Javier A ^b   Takayanagui, Osvaldo M ^d   Bonato, Pierina S ^d   Horton, John ^e   Saavedra, Herbert ^a   Gonzalez, Armando E ^f   Gilman, Robert H ^b,g  

^a INSTITUTO NACIONAL DE CIENCIAS NEUROLÓGICAS   (Peru)

^b UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^c California   (Peru)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e Tropical Projects   (United Kingdom)

^f UNIVERSIDAD NACIONAL MAYOR DE SAN MARCOS   (Peru)

^g JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Albendazole; Neurocysticercosis; Peru; Praziquantel; Taenia solium

Indexed keywords

ALBENDAZOLE SULFOXIDE; CARBAMAZEPINE; DEXAMETHASONE; PHENYTOIN; PRAZIQUANTEL; RANITIDINE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; INTRACRANIAL HYPERTENSION; MALE; NEUROCYSTICERCOSIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ALBENDAZOLE; ANIMALS; ANTHELMINTICS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; NEUROCYSTICERCOSIS; PERU; PRAZIQUANTEL; TAENIA SOLIUM; YOUNG ADULT;

EID: 79958729486     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.03945.x     Document Type: Article

References (31)

1. Commission on Tropical Diseases of the International League Against Epilepsy. Relationship between epilepsy and tropical diseases. Commission on Tropical Diseases of the International League Against Epilepsy. Epilepsia 1994; 35: 89-93.
2. Garcia HH, Pretell EJ, Gilman RH, Martinez SM, Moulton LH, Del Brutto OH, Herrera G, Evans CA, Gonzalez AE. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med 2004; 350: 249-58.
3. Del Brutto OH, Roos KL, Coffey CS, Garcia HH. Meta-analysis: cysticidal drugs for neurocysticercosis: albendazole and praziquantel. Ann Intern Med 2006; 145: 43-51.
4. Sotelo J, del Brutto OH, Penagos P, Escobedo F, Torres B, Rodriguez-Carbajal J, Rubio-Donnadieu F. Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis. J Neurol 1990; 237: 69-72.
5. Homeida M, Leahy W, Copeland S, Ali MM, Harron DW. Pharmacokinetic interaction between praziquantel and albendazole in Sudanese men. Ann Trop Med Parasitol 1994; 88: 551-9.
6. Pengsaa K, Na-Bangchang K, Limkittikul K, Kabkaew K, Lapphra K, Sirivichayakul C, Wisetsing P, Pojjaroen-Anant C, Chanthavanich P, Subchareon A. Pharmacokinetic investigation of albendazole and praziquantel in Thai children infected with Giardia intestinalis. Ann Trop Med Parasitol 2004; 98: 349-57.
7. Na-Bangchang K, Kietinun S, Pawa KK, Hanpitakpong W, Na-Bangchang C, Lazdins J. Assessments of pharmacokinetic drug interactions and tolerability of albendazole, praziquantel and ivermectin combinations. Trans R Soc Trop Med Hyg 2006; 100: 335-45.
8. Taylor DH, Morris DL. Combination chemotherapy is more effective in postspillage prophylaxis for hydatid disease than either albendazole or praziquantel alone. Br J Surg 1989; 76: 954.
9. Ayles HM, Corbett EL, Taylor I, Cowie AG, Bligh J, Walmsley K, Bryceson AD. A combined medical and surgical approach to hydatid disease: 12 years' experience at the Hospital for Tropical Diseases, London. Ann R Coll Surg Engl 2002; 84: 100-5.
10. Lam KS, Faraj A, Mulholland RC, Finch RG. Medical decompression of vertebral hydatidosis. Spine 1997; 22: 2050-5.
11. Chawla A, Maheshwari M, Parmar H, Hira P, Hanchate V. Imaging features of disseminated peritoneal hydatidosis before and after medical treatment. Clin Radiol 2003; 58: 818-20.
12. Miquel J, Gil-Grande LA, Retamar A, Garcia-Hoz F, del Pozo D, Pena E. [Response of multiorganic hydatdosis to combined therapy with albendazole and praziquantel]. Enferm Infecc Microbiol Clin 2001; 19: 139-40.
13. Schaub NA, Perruchoud AP, Buechner SA. Cutaneous larva migrans associated with Loffler's syndrome. Dermatology 2002; 205: 207-9.
14. Li S, He G, Lu Z, Li Z, Tao Y, Zhang L, Zhu F. [Efficacy of praziquantel combined with albendazole in the treatment of clonorchiasis]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 1995; 13: 61-3.
15. Kaur S, Singhi P, Singhi S, Khandelwal N. Combination therapy with albendazole and praziquantel versus albendazole alone in children with seizures and single lesion neurocysticercosis: a randomized, placebo-controlled double blind trial. Pediatr Infect Dis J 2009; 28: 403-6.
16. Guo DM, Xie SP, Jia JP. [Therapeutic efficacy of praziquantel, albendazole and a combination of the two drugs in cysticercosis]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2003; 21: 187-8.
17. Venkatesan P. Albendazole. J Antimicrob Chemother 1998; 41: 145-7.
18. Mares SS, Jung CH, López AT, González-Esquivel DF. Influence of a Mexican diet on the bioavailability of albendazole. Basic Clin Pharmacol Toxicol 2005; 97: 122-4.
19. Castro N, Medina R, Sotelo J, Jung H. Bioavailability of praziquantel increases with concomitant administration of food. Antimicrob Agents Chemother 2000; 44: 2903-4.
20. Bonato PS, de Oliveira AR, de Santana FJ, Fernandes BJ, Lanchote VL, Gonzalez AE, Garcia HH, Takayanagui OM. Simultaneous determination of albendazole metabolites, praziquantel and its metabolite in plasma by high-performance liquid chromatography-electrospray mass spectrometry. J Pharm Biomed Anal 2007; 44: 558-63.
21. Rawden HC, Kokwaro GO, Ward SA, Edwards G. Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes. Br J Clin Pharmacol 2000; 49: 313-22.
22. Steiger U, Cotting J, Reichen J. Albendazole treatment of echinococcosis in humans: effects on microsomal metabolism and drug tolerance. Clin Pharmacol Ther 1990; 47: 347-53.
23. Gottschall DW, Theodorides VJ, Wang R. The metabolism of benzimidazole anthelmintics. Parasitol Today 1990; 6: 115-24.
24. Ridtitid W, Ratsamemonthon K, Mahatthanatrakul W, Wongnawa M. Pharmacokinetic interaction between ketoconazole and praziquantel in healthy volunteers. J Clin Pharm Ther 2007; 32: 585-93.
25. Masimirembwa CM, Hasler JA. Characterisation of praziquantel metabolism by rat liver microsomes using cytochrome P450 inhibitors. Biochem Pharmacol 1994; 48: 1779-83.
26. Ridtitid W, Wongnawa M, Mahatthanatrakul W, Punyo J, Sunbhanich M. Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin Pharmacol Ther 2002; 72: 505-13.
27. Castro N, Márquez-Caraveo C, Brundage RC, González-Esquivel D, Suárez AM, Góngora F, Jara A, Urizar J, Lanao JM, Jung H. Population pharmacokinetics of albendazole in patients with neurocysticercosis. Int J Clin Pharmacol Ther 2009; 47: 679-85.
28. Yap KY, Chui WK, Chan A. Drug interactions between chemotherapeutic regimens and antiepileptics. Clin Ther 2008; 30: 1385-407.
29. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006; 61: 246-55.
30. Bittencourt PRM, Gracia CM, Martins R, Fernandes AG, Diekmann HW, Jung W. Phenytoin and carbamazepine decrease oral bioavailability of praziquantel. Neurology 1992; 42: 492-6.
31. Lima RM, Ferreira MA, de Jesus Ponte Carvalho TM, Dumêt Fernandes BJ, Takayanagui OM, Garcia HH, Coelho EB, Lanchote VL. Albendazole-praziquantel interaction in healthy volunteers: kinetic disposition, metabolism and enantioselectivity. Br J Clin Pharmacol 2011; 71: 528-35.